Nectar Lifesciences

₹33.3 -0.2 | 0.5%

WEBSITE BSE:532649 NSE : NECTAR LIFE 10 May, 16:01

Market Cap ₹746 Cr.

Stock P/E 92.3

P/B 0.7

Current Price ₹33.3

Book Value ₹ 47.7

Face Value 1

52W High ₹45.7

Dividend Yield 0%

52W Low ₹ 16.4

Edit Ratio

Nectar Lifesciences Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Nectar Lifesciences Ltd is a pharmaceutical business enterprise. The Company is engaged in supplying pills and pharmaceuticals. It operates within the business phase of Pharmaceuticals Products. The Company's commercial enterprise activities encompass agreement research and manufacturing offerings, API and intermediates, formulations, generics and over the counter (OTC), diagnostics, empty hard gelatin drugs and menthol. Its merchandise encompass Cefixime Trihydrate, Cefuroxime Axetil (Amorphous), Cefpodoxime Proxetil, Cefuroxime Sodium (Sterile), Ceftazidime (Buffered), Cephalothin (Buffered), Cefazolin Sodium (Sterile), Cefprozil, Cefoperzone Sodium (Sterile), Cefpirome Sulphate (Buffered) and Cefoxitin Sodium (Sterile). It gives contract manufacturing skills for solid dosage forms, inclusive of capsules, pills, dry powder oral suspension and granules and injectible for cephalosporins. Its subsidiaries consist of Nectar Lifesciences UK Ltd and Nectar Lifesciences US, LLC.

Nectar Lifesciences Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Nectar Lifesciences Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	365	443	476	403	389	344	389	394	398	452
Other Income	5	1	1	0	11	13	18	0	11	0
Total Income	370	444	477	403	399	357	407	395	409	453
Total Expenditure	337	396	427	361	396	343	371	359	371	410
Operating Profit	33	47	50	42	3	15	36	36	37	43
Interest	18	18	17	21	21	17	20	18	21	25
Depreciation	14	14	14	15	15	15	15	15	15	15
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	0	15	18	6	-32	-18	2	3	2	2
Provision for Tax	-1	5	6	2	-10	-8	-2	1	1	1
Profit After Tax	2	10	12	4	-22	-9	4	2	1	2
Adjustments	-0	-0	0	0	-0	0	0	-0	-0	0
Profit After Adjustments	2	10	12	4	-22	-9	4	2	1	2
Adjusted Earnings Per Share	0.1	0.4	0.5	0.2	-1	-0.4	0.2	0.1	0	0.1

Nectar Lifesciences Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	1626	1638	1644	1676	1644	1876	2783	2366	1543	1669	1524	1633
Other Income	16	13	20	6	23	6	6	4	11	11	43	29
Total Income	1642	1651	1664	1681	1666	1882	2789	2371	1555	1680	1567	1664
Total Expenditure	1336	1350	1377	1437	1419	1640	2519	2147	1442	1510	1471	1511
Operating Profit	306	300	287	245	247	242	270	224	113	170	96	152
Interest	115	138	126	123	117	115	148	126	112	79	79	84
Depreciation	76	84	77	57	62	64	63	61	60	57	59	60
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	-25	0	0	0
Profit Before Tax	115	78	85	64	67	63	59	37	-85	34	-42	9
Provision for Tax	29	16	18	10	12	10	11	6	-12	9	-18	1
Profit After Tax	86	62	66	54	55	52	48	32	-73	25	-24	9
Adjustments	0	0	0	0	0	0	0	1	0	0	0	0
Profit After Adjustments	86	62	66	54	55	52	48	32	-73	25	-24	9
Adjusted Earnings Per Share	3.8	2.8	3	2.4	2.5	2.3	2.1	1.4	-3.3	1.1	-1.1	0.4

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-9%	-14%	-4%	-1%
Operating Profit CAGR	-44%	-25%	-17%	-11%
PAT CAGR	-196%	NAN%	NAN%	NAN%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	94%	8%	15%	2%
ROE Average	-2%	-2%	0%	4%
ROCE Average	2%	3%	6%	8%

Nectar Lifesciences Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	868	927	958	954	1007	1059	1105	1136	1062	1088	1065
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	261	223	266	245	164	220	166	121	128	291	226
Other Non-Current Liabilities	101	118	131	117	132	136	134	128	-2	5	-13
Total Current Liabilities	1045	1126	1156	1240	1279	1309	1300	1248	1187	1004	891
Total Liabilities	2274	2394	2510	2556	2581	2724	2705	2633	2376	2388	2169
Fixed Assets	914	948	934	906	881	852	825	785	772	723	662
Other Non-Current Assets	209	209	172	186	204	211	211	233	365	310	275
Total Current Assets	1151	1237	1369	1464	1496	1661	1669	1615	1239	1355	1231
Total Assets	2274	2394	2510	2556	2581	2724	2705	2633	2376	2388	2169

Nectar Lifesciences Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	26	6	10	33	37	13	9	21	21	26	18
Cash Flow from Operating Activities	361	255	144	169	199	65	239	285	21	95	134
Cash Flow from Investing Activities	-99	-90	-60	-77	-18	-29	-26	-33	-29	17	52
Cash Flow from Financing Activities	-282	-161	-61	-89	-204	-40	-201	-252	11	-119	-186
Net Cash Inflow / Outflow	-20	4	23	3	-23	-4	12	-0	4	-8	-0
Closing Cash & Cash Equivalent	6	10	33	37	13	9	21	21	26	18	18

Nectar Lifesciences Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	3.82	2.77	2.95	2.42	2.47	2.33	2.12	1.44	-3.27	1.12	-1.08
CEPS(Rs)	7.21	6.52	6.37	4.98	5.24	5.2	4.94	4.13	-0.58	3.66	1.56
DPS(Rs)	0.1	0.1	0.1	0.1	0.05	0.05	0.05	0.05	0	0	0
Book NAV/Share(Rs)	38.69	41.34	41.11	42.54	44.89	47.21	49.28	50.66	47.36	48.51	47.47
Core EBITDA Margin(%)	17.33	16.85	15.28	13.32	12.87	11.28	8.49	8.31	5.75	8.23	3.03
EBIT Margin(%)	13.75	12.65	12.04	10.44	10.6	8.5	6.65	6.18	1.55	5.86	2.12
Pre Tax Margin(%)	6.85	4.58	4.85	3.56	3.87	2.99	1.89	1.42	-4.81	1.77	-2.43
PAT Margin (%)	5.12	3.63	3.79	3.03	3.17	2.5	1.53	1.2	-4.15	1.3	-1.38
Cash Profit Margin (%)	9.66	8.56	8.17	6.23	6.74	5.57	3.56	3.5	-0.74	4.26	2
ROA(%)	3.9	2.66	2.7	2.14	2.15	1.97	1.75	1.19	-2.93	1.05	-1.06
ROE(%)	10.38	6.92	7.17	5.78	5.64	5.06	4.4	2.84	-6.67	2.33	-2.25
ROCE(%)	12.88	12.24	11.58	9.95	9.73	9.13	10.29	8.32	1.41	5.77	1.97
Receivable days	71.26	77.54	85.98	95.49	103.72	96.93	68.64	65.92	79.75	77.89	75.92
Inventory Days	138.12	153.2	161.85	165.71	176.99	149.46	104.21	130.89	161.98	118.26	139.23
Payable days	92.2	130.01	143.21	148.03	162.04	142.52	84.19	99.25	137.11	107.25	109.47
PER(x)	4.09	8.74	12.49	15.71	14.26	11.35	8.06	6.86	0	21.53	0
Price/Book(x)	0.4	0.59	0.9	0.89	0.78	0.56	0.35	0.2	0.39	0.5	0.33
Dividend Yield(%)	0.64	0.41	0.27	0.26	0.14	0.19	0.29	0.51	0	0	0
EV/Net Sales(x)	0.75	0.85	1.05	1.06	1.01	0.82	0.45	0.41	0.84	0.83	0.72
EV/Core EBITDA(x)	4	4.63	5.99	7.27	6.7	6.35	4.68	4.37	11.48	8.13	11.35
Net Sales Growth(%)	23.85	0.74	0.33	1.95	-1.91	14.15	48.32	-14.97	-34.78	8.13	-8.7
EBIT Growth(%)	14.73	-6.09	-2.72	-11.03	-1.23	-3.76	16.34	-21.1	-83.3	314	-67.17
PAT Growth(%)	17.11	-27.59	6.73	-18.15	2.02	-5.54	-8.94	-33.22	-330.47	134.19	-196.55
EPS Growth(%)	17.11	-27.59	6.73	-18.15	2.03	-5.54	-8.94	-32.1	-326.69	134.19	-196.54
Debt/Equity(x)	1.01	0.93	1	1.01	0.87	0.9	0.82	0.69	0.85	0.79	0.71
Current Ratio(x)	1.1	1.1	1.18	1.18	1.17	1.27	1.28	1.29	1.04	1.35	1.38
Quick Ratio(x)	0.45	0.43	0.5	0.51	0.5	0.61	0.58	0.51	0.55	0.69	0.63
Interest Cover(x)	1.99	1.57	1.67	1.52	1.57	1.54	1.4	1.3	0.24	1.43	0.47
Total Debt/Mcap(x)	2.51	1.58	1.12	1.13	1.11	1.61	2.36	3.51	2.17	1.59	2.12

Nectar Lifesciences Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	44.35	44.35	44.35	44.35	44.35	44.35	44.35	44.35	44.35	44.35
FII	1.21	1.32	1.18	12.81	12.7	12.77	12.71	12.73	12.81	13.49
DII	0	0	0	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Public	33.92	33.81	33.95	22.3	22.41	22.34	22.4	22.39	22.31	21.63
Others	20.51	20.51	20.51	20.51	20.51	20.51	20.51	20.51	20.51	20.51
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	9.95	9.95	9.95	9.95	9.95	9.95	9.95	9.95	9.95	9.95
FII	0.27	0.3	0.26	2.87	2.85	2.86	2.85	2.85	2.87	3.03
DII	0	0	0	0	0	0	0	0	0	0
Public	7.61	7.58	7.61	5	5.03	5.01	5.02	5.02	5	4.85
Others	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.6
Total	22.43	22.43	22.43	22.43	22.43	22.43	22.43	22.43	22.43	22.43

Pros

Stock is trading at 0.7 times its book value
Company has reduced debt.

Cons

Promoter holding is low: 44.35%.
Company has a low return on equity of -2% over the last 3 years.
Debtor days have increased from 107.25 to 109.47days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Nectar Lifesciences News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Nectar Lifesciences

Add Watchlist

Nectar Lifesciences Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Nectar Lifesciences Share Price

Alert Data

Quarterly Price

Peer Comparison

Nectar Lifesciences Quarterly Results

Nectar Lifesciences Profit & Loss

Growth Rates

Nectar Lifesciences Balance Sheet

Nectar Lifesciences Cash Flow

Nectar Lifesciences Ratios

Nectar Lifesciences Shareholding Pattern

Nectar Lifesciences News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!